Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

By Uno Tsukasa   Niioka Takenori   Hayakari Makoto   Yasui-Furukori Norio   Sugawara Kazunobu   Tateishi Tomonori  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 143-149

Springer Publishing Company

Access to resources Recommend Favorite

Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

By Giancarlo Gina M.   Venkatakrishnan Karthik   Granda Brian W.   von Moltke Lisa L.   Greenblatt David J.  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 1, 2001-04 ,pp. : 31-36

Springer Publishing Company

Access to resources Recommend Favorite

Metabolism of R- and S-Warfarin by CYP2C19 into Four Hydroxywarfarins

By  

Drug Metabolism Letters, Vol. 6, Iss. 3, 2012-09 ,pp. : 157-164

Bentham Science Publishers

Access to resources Recommend Favorite

A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 5, 2015-01 ,pp. : 306-309

Govi-Verlag

Access to resources Recommend Favorite

Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 4, 2010-12 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite